The persistence of hemodynamically significant patent ductus arteriosus (НPDA) has a great value on a short term and long term outcomes in preterm infant. There is no hesitation that PDA should be closed pharmacologically or surgically if present. The aim of the study was to establish the advisability, efficiency and safety of using different volumes of infusion in combination with COX inhibitors and to determine its effect on the timing of the НPDA closure. Retrospectively has been studied 91 preterm infants with gestational age 26-31 weeks, manifestations of respiratory distress syndrome, НPDA treated at the NICU. The research groups were representative for gestational age, gender and weight (1205.0 ± 435.0 grams). The ...
Background: Patency of ductus arteriosus is vital for fetal survival. Ductus often fails to close in...
Background: Much controversy exists about the optimal management of a patent ductus arteriosus (FDA)...
Background: Much controversy exists about the optimal management of a patent ductus arteriosus (FDA)...
The persistence of hemodynamically significant patent ductus arteriosus (НPDA) has a great value on ...
Closure of hemodynamically significant patent ductus arterios (HSPDA) is one of the most important ...
Closure of hemodynamically significant patent ductus arterios (HSPDA) is one of the most important ...
_Background:_ Much controversy exists about the optimal management of a patent ductus arteriosus (PD...
We read with great interest the systematic review and meta-analysis by Mitra et-al published recentl...
We read with great interest the systematic review and meta-analysis by Mitra et-al published recentl...
Background: Much controversy exists about the optimal management of a patent ductus arteriosus (FDA)...
Background: Patent ductus arteriosus (PDA) is a common problem encountered in premature infants, esp...
Abstract Background Much controversy exists about the optimal management of a patent ductus arterios...
AbstractBackground aim of the studyPatent ductus arteriosus (PDA), a common finding among premature ...
ObjectiveTo determine whether a nonintervention approach for treating hemodynamically significant pa...
Background: Much controversy exists about the optimal management of a patent ductus arteriosus (FDA)...
Background: Patency of ductus arteriosus is vital for fetal survival. Ductus often fails to close in...
Background: Much controversy exists about the optimal management of a patent ductus arteriosus (FDA)...
Background: Much controversy exists about the optimal management of a patent ductus arteriosus (FDA)...
The persistence of hemodynamically significant patent ductus arteriosus (НPDA) has a great value on ...
Closure of hemodynamically significant patent ductus arterios (HSPDA) is one of the most important ...
Closure of hemodynamically significant patent ductus arterios (HSPDA) is one of the most important ...
_Background:_ Much controversy exists about the optimal management of a patent ductus arteriosus (PD...
We read with great interest the systematic review and meta-analysis by Mitra et-al published recentl...
We read with great interest the systematic review and meta-analysis by Mitra et-al published recentl...
Background: Much controversy exists about the optimal management of a patent ductus arteriosus (FDA)...
Background: Patent ductus arteriosus (PDA) is a common problem encountered in premature infants, esp...
Abstract Background Much controversy exists about the optimal management of a patent ductus arterios...
AbstractBackground aim of the studyPatent ductus arteriosus (PDA), a common finding among premature ...
ObjectiveTo determine whether a nonintervention approach for treating hemodynamically significant pa...
Background: Much controversy exists about the optimal management of a patent ductus arteriosus (FDA)...
Background: Patency of ductus arteriosus is vital for fetal survival. Ductus often fails to close in...
Background: Much controversy exists about the optimal management of a patent ductus arteriosus (FDA)...
Background: Much controversy exists about the optimal management of a patent ductus arteriosus (FDA)...